GlobalData has estimated that the global Crohn’s Disease therapeutics market was worth $4.4 billion in 2012
GlobalData estimates that the global GVHD therapeutics market was worth $261.6m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.3% to reach $615.1m by 2018.
Bell Potter has previously noted (Feb 2014) in one of their research reports that GVHD could be a US$300 - $600m and Crohns Disease a US$2.4bn market. In Bell Potters 12 month price target (approx. $9 +), Prochymal has not been factored into their valuation and noted as such -
Based on recent 29/4/14 ASX release ..and CNBC interviews (all posted before) SI quite excited by the potential of Prochymal...in fact MSB's evaluation of the Osiris data at the time , was a major reason why they outlaid $50M + in acquiring their MSC technology.
On 28/5/2014 ASX release about MSB also accelerating there manufacturing plans in Singapore also made reference to Prochymal.
Please DYOR and GLTAH.
Prochymal, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |